Pharmaceutical

Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug

3 monthes ago   |   By Xconomy

Deciphera Pharmaceuticals this morning announced plans to seek FDA approval of a cancer medicine that treats a deadly type of tumor that forms in the gastrointestinal tract. The Deciphera drug, ripretinib, hit its main goal in a Phase 3 trial, INVICTUS, in 129 patients with gastrointestinal stromal tumors who have failed at least three treatments. Ripretinib kept tumors from spreading-what's known as progression-free survival-for a median of 6.3 months , compared to a median of 1 month for placebo patients. GIST patients on Deciphera's drug were...
Read more ...

 

Deciphera soars as phase 3 cancer data tee up FDA filing

Deciphera soars as phase 3 cancer data tee up FDA filing

3 monthes ago   |   By Fierce Biotech

A phase 3 trial of Deciphera's ripretinib in gastrointestinal stromal tumors has hit its primary endpoint. The data sparked a surge in the company's stock price, even though details of the results leave scope to question ripretinib's prospects.
Read more ...

 


Search by Tags

   Pharmaceutical      Pharmaceuticals      Cancer      Drug      Drugs      Medicine      Boston      Boston blog main      National blog main      Andrew Berens      Avapritinib      Blueprint Medicines      Cancer      Clinical trials      Deciphera Pharmaceuticals      Gastrointestinal stromal tumor      Gist      Gleevec      Imatinib      Life Sciences      Regorafenib      Ripretinib      Steve Hoerter      Stivarga      Sunitinib      Sutent      SVB Leerink  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

IAmScience Mannie Liscum

IAmScience Mannie Liscum

For Mannie Liscum, thinking is a privilege, and his job gives him the chance to be fascinated by human's capacity to conceptualize and learn new things. “It's my goal to use as... Read more ...

3 Takeaways From the Resurrection of Biogen's Alzheimer's Drug

3 Takeaways From the Resurrection of Biogen's Alzheimer's Drug

The name of the experimental drug was heard so frequently in hotel hallways at the conference that it sounded like an incantation: aducanumab, aducanumab, aducanumab... Read more ...

Acadia Looks to Expand Drug Beyond Parkinson's Disease Psychosis

Acadia Looks to Expand Drug Beyond Parkinson's Disease Psychosis

Acadia Pharmaceuticals revealed late-stage clinical data this week that could support bringing its drug for psychosis to a broader group of patients. The Acadia drug... Read more ...

FDA Puts Partial Hold on Tests of Ipsen Drug Acquired in $1B Deal

FDA Puts Partial Hold on Tests of Ipsen Drug Acquired in $1B Deal

Two clinical trials testing an Ipsen drug in rare connective tissue disorders have been placed on partial hold after safety concerns about chronic dosing of the compound... Read more ...

Bio Roundup: Biogen at CTAD, Sage's Stumble, Astellas's $3B Offer & More

Bio Roundup: Biogen at CTAD, Sage's Stumble, Astellas's $3B Offer & More

It's been a roller-coaster year for those hoping for new drugs to treat Alzheimer's disease, a leading cause of death with rising treatment costs and no clear answer yet as to... Read more ...

A Powerhouse of Cancer Research: A View from Florida

A Powerhouse of Cancer Research: A View from Florida

Nearly everyone has been affected by cancer , either through a personal diagnosis or that of a loved one. In the U.S., 1.7 million people are diagnosed each year, and over 15... Read more ...

Biogen Points to Enrollment and Dosing to Explain Alzheimer's Results

Biogen Points to Enrollment and Dosing to Explain Alzheimer's Results

Biogen revealed detailed results from its Alzheimer's trial to a jam-packed room of eager conference attendees this week-and while some described it as a major advance in the... Read more ...

Family with Two Rare Syndromes Reveals Immunity Glitch

Family with Two Rare Syndromes Reveals Immunity Glitch

Members of a three-generation family in France who suffer from widespread infections and fragile skin, joints, bones, and blood vessels share an underlying and unexpected... Read more ...

Application of A KNN‐based Similarity Method to Biopharmaceutical Manufacturing

Abstract Machine learning based similarity analysis is commonly found in many artificial intelligence applications like the one utilized in e‐commerce and digital marketing. In... Read more ...

Scientists detail how chromosomes reorganize after cell division

Researchers have discovered key mechanisms and structural details of a fundamental biological process - how a cell nucleus and its chromosomal material reorganizes itself after... Read more ...